Icahn begins his assault on Forest Labs CEO

Once it became apparent that Carl Icahn had accumulated a significant stake in Forest Labs, the analysts sat back waiting for the other shoe to drop. That happened today, as Icahn targeted Forest CEO Howard Solomon for a long litany of abuses: From trouble with the feds to a "poor" record on earnings. Icahn has made a fortune toppling biopharma CEOs at Biogen Idec and Genzyme. And with close to 7 percent of Forest's shares in his portfolio, it appears that the 83-year-old Solomon is now in for the Icahn treatment. Story

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.